Glioblastoma Multiforme Market: Cancer Immunotherapies Dominate First-in-Class Product Innovation

USA - English

• India - English

PUNE, India, October 4, 2016 /PRNewswire/ --

ReportnReports.com adds a Frontier Pharma report on Glioblastoma Multiforme Market stating that the glioblastoma therapy pipeline, which includes 512 products active across all stages of development, is moderately sized but highly innovative. Potential factors driving the pipeline include vast unmet need, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market landscape, and a recently improved understanding of the disease pathophysiology, facilitating the development of novel compounds.

Complete report on Glioblastoma Multiforme Market with 13 market data tables and 36 figures, spread across 73 pages is available at http://www.reportsnreports.com/reports/700757-frontier-pharma-glioblastoma-multiforme-cancer-immunotherapies-dominate-first-in-class-product-innovation.html .

Glioblastoma, a particularly aggressive form of brain tumor, has a promising treatment pipeline, with 120 first-in-class programs acting on 86 first-in-class molecular targets. Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas. It has a peak incidence between 55 and 84 years of age, with the median age of diagnosis being 64 years. In the US and EU, the annual incidence was estimated to be three to four cases per 100,000 people. GBM has a high degree of intratumoral heterogeneity, which is associated with poor prognosis and the development of drug resistance.

The GBM market is characterized by a small selection of marketed product options, consisting of chemotherapies, cancer immunotherapies and receptor tyrosine kinase inhibitor products. The pipeline is moderately large, with 512 products active across all stages of development. First-in-class products only constitute approximately a quarter of the pipeline, and represent 31% of products with a disclosed target. The most widely studied group of first-in-class targets are the receptor tyrosine kinase and ligand inhibitors, a trend that has been heavily influenced by the success of Avastin, and possibly successful EGFR inhibitors such as Tarceva that are used in the treatment of other oncology indications.

Potential driving factors for the market include a typically poor outcome for treated patients, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market, and a strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fulfill the unmet needs.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=700757 .

Overall, due to the highly complex and polygenic nature of GBM, which has numerous subtype classifications, it is unlikely that the inhibition of a single target will be sufficient to substantially improve patient prognosis. Instead, it is more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, may improve treatment outcomes. First-in-class targets analyzed in this report have shown encouraging efficacy profiles, and some show the ability to chemosensitize cancer cells.

Another newly published market research report titled on Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market states that this strong growth will occur in spite of a number of key patent expirations for drugs including Rituxan, Gleevec and Velcade, as new drugs hit the market and the prevalence of hematological cancers increases. The market for hematological cancers, which covers leukemia, lymphoma and myeloma, is expected to more than double from $30.7 billion in 2015 to $70.1 billion by 2022, representing a compound annual growth rate of 12.5%. Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development. Hematological Cancers Market research report of 147 pages is available at http://www.reportsnreports.com/reports/572051-global-hematological-cancers-market-to-2022-commercially-successful-targeted-therapies-and-large-innovative-pipeline-to-drive-market.html .

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
2nd floor, metropole, Next to inox theatre, Bund garden road,
Pune-411001
Maharashtra, India.
Tel:  +1-888-391-5441
[email protected]

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports